Clinical trials: Acute Exacerbation
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Bronchitis, Chronic
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin…
- Trial name
- NCT00846911
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 8 sites in Albania, Bosnia and Herzegovina and 6 more
- Volunteers
- 2,672 people
- Sponsor
- Bayer
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01234779
- Testing
- bitopertin [RO4917838], olanzapine
- Where
- 46 sites in United States, Romania and 3 more
- Volunteers
- 301 people
- Sponsor
- Hoffmann-La Roche
Chronic Rhinosinusitis With Nasal Polyps
Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis
TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens.
- Trial name
- NCT05355207
- Testing
- TRL1068
- Volunteers
- 12 people
- Sponsor
- Trellis Bioscience LLC
Schizophrenia
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously…
- Trial name
- PRISMA-3_OLE (NCT03870880)
- Testing
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 24 sites in United States, Ukraine
- Volunteers
- 215 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
- Trial name
- NCT02477020
- Testing
- TAK-063 20 mg
- Where
- 15 sites in United States
- Volunteers
- 164 people
- Sponsor
- Takeda